PML-driven sumoylation of PML::RARA-bound repressors and hematopoietic progenitor immortalization

Introduction and publication metadata

This PubMed entry (PMID 42663568; DOI 10.1084/jem.20252333) references a 2026 Journal of Experimental Medicine article titled “PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization.” The article was published in the 2026 Sep 7 issue (223[9]:e20252333) and was made available online on 2026 Aug 28.

The supplied source content on PubMed contains the article title, author list, affiliations, journal citation, PMID and DOI. The visible abstract in the provided content is truncated and does not include the study’s full abstract, methods, results, or conclusions.

Study focus implied by title: PML::RARA, PML-driven sumoylation, and progenitor immortalization

The article title conveys a mechanistic relationship in which PML-driven sumoylation acts on repressors that are bound to the PML::RARA fusion, and that this molecular event is involved in driving hematopoietic progenitor immortalization. The title therefore indicates the study addresses molecular mechanisms linking the PML::RARA fusion protein—classically associated with acute promyelocytic leukemia (APL)—to changes in post-translational modification (sumoylation) of transcriptional repressors and to an outcome relevant to leukemic transformation (progenitor immortalization).

No additional experimental details, specific targets, biochemical data (for example, which SUMO isoforms, SUMO E3 ligases, or specific repressors), model systems (cell lines, primary cells, or in vivo models), or quantitative results are available in the provided PubMed capture. The title alone does not specify whether the findings were demonstrated in human samples, mouse models, or in vitro systems.

Author list and institutional affiliations

The article lists multiple authors, including Hsin Chieh Wu, Emmanuel Laplantine, Cécile Esnault, Michiko Niwa-Kawakita, Yi Zhang, Viviane De Almeida Bastos, Marie-Claude Geoffroy, and Hugues de Thé among others. The affiliations provided in the source include Collège de France (Oncologie Cellulaire et Moléculaire, PSL University, CIRB, INSERM UMR 1050, CNRS UMR 7241), Université Paris-Cité (INSERM U1342, CNRS EMR8000, Institut de Recherche Saint-Louis, Hôpital Saint-Louis), Sorbonne Université (UMS 37 PASS, P3S, INSERM), and the Laboratoire d'hématologie Moléculaire at Assistance Publique–Hôpitaux de Paris, Hôpital St. Louis. Two authors are noted as having contributed equally.

Publication dates, identifiers, and journal citation

• Journal: Journal of Experimental Medicine (J Exp Med)
• Publication date: 2026 Sep 7; article e20252333
• Epub date: 2026 Aug 28
• DOI: 10.1084/jem.20252333
• PubMed ID (PMID): 42663568

These identifiers enable retrieval of the full article for verification of experimental design, methods, and data.

Limitations of provided source text and missing details

The content supplied from PubMed is truncated: the abstract and the full text are not present in the provided capture. Consequently, the following were not reported in the source content available here and cannot be inferred safely:

• The specific repressors bound by PML::RARA that are subject to sumoylation.
• The experimental systems used (primary hematopoietic progenitors, cell lines, animal models, or patient samples).
• The molecular or cellular assays and controls employed to establish causality (for example, loss- or gain-of-function experiments, use of sumoylation mutants, or pharmacologic inhibitors).
• Quantitative outcomes, statistical analyses, effect sizes, and reproducibility measures.
• Any proposed therapeutic implications, clinical correlations, or recommendations.

Because these critical details are absent from the provided material, readers should consult the full published article (DOI 10.1084/jem.20252333) to access the complete abstract, methods, results, figures, and discussion.

Clinical and research implications (interpretive summary and recommended next steps)

Based on the title alone, the study addresses a mechanism by which the PML::RARA oncoprotein may co-opt post-translational modification pathways—specifically sumoylation—to alter the activity of transcriptional repressors and promote a cellular phenotype consistent with transformation or immortalization of hematopoietic progenitors. This topic is directly relevant to understanding the molecular pathogenesis of acute promyelocytic leukemia (APL) and could have implications for targeted strategies that interfere with PML, sumoylation machinery, or the identified repressors.

However, the current source does not provide the experimental evidence or data needed to evaluate the strength of the findings, translational potential, or limitations. Recommended next steps for a clinical or research reader seeking to act on this information:

• Retrieve and read the full article using the DOI or PMID to examine experimental design, models, and data.
• Assess whether the authors identify specific repressors and sumoylation machinery that are amenable to pharmacologic targeting.
• Evaluate whether the findings were validated in primary patient material or relevant in vivo models, and whether there are data linking the mechanism to clinical outcomes.

Note: The summary and interpretation above are strictly derived from the article title and the limited metadata available in the provided PubMed capture. Full experimental details and conclusions were not reported in the supplied source text and therefore are not presented here.